Blocking Enzyme Speeds Breakdown of Leukemia Growth Protein
Researchers have discovered that the enzyme PTPN2 stabilizes a protein called c-MYC, which promotes leukemia cell growth. Inhibiting this enzyme in preclinical models successfully slowed the progression of acute myeloid leukemia.
Why it matters
This discovery offers a potential new therapeutic target for treating aggressive blood cancers that are currently resistant to standard chemotherapy.
A research team has identified an enzyme that helps acute myeloid leukemia (AML) cells survive by protecting c-MYC, a protein that drives cell growth, from degradation. The enzyme, known as protein tyrosine phosphatase non-receptor type 2 (PTPN2), removes a phosphate group that helps mark c-MYC for breakdown. Reducing PTPN2 levels slowed leukemia cell growth and increased programmed cell death in laboratory experiments, while an experimental compound that inhibits the enzyme slowed the growth of human leukemia cell implants in mice. The findings point to a potential way to weaken c-MYC-driven growth and provide a starting point for developing more selective inhibitors.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in